At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Trial of ARQ 197 (Tivantinib)/Cetuximab Versus Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer
In Brief
A Phase 2 clinical trial evaluating Cetuximab, Laboratory Biomarker Analysis, and 1 other intervention for Head and Neck Squamous Cell Carcinoma and Recurrent Head and Neck Carcinoma. Completed, enrolled 81 participants across 24 sites.
Detailed Summary
This randomized phase II trial studies how well cetuximab with or without tivantinib works in treating patients with head and neck cancer that has come back (recurrent), has spread to other places in the body (metastatic), or cannot be removed by surgery. Monoclonal antibodies, such as cetuximab, may interfere with the ability of tumor cells to grow and spread. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether cetuximab is more effective with or without tivantinib in treating patients with head and neck cancer.
Study Details
Timeline
Interventions
Given IV
Correlative studies
Given PO